Purpose: To develop a supervised machine learning algorithm capable of predicting above vs.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) carries among the poorest prognoses of all cancers. Tumors exhibit significant heterogeneity on a genetic, transcriptomic and proteomic level, which manifests itself in a complex tissue architecture including tumor cells, various fibroblast and immune cell populations embedded in a poorly vascularized, dense stroma (1).
Despite its overall dismal prognosis, recent research has identified specific molecular subtypes with distinct therapy response and outcome. Among these, the so-called classical phenotype shows improved chemotherapy response and survival compared to the so-called quasimesenchymal or basal-like subtype underlining the urgent requirement for advanced techniques for precise pretherapeutic patient stratification (2, 3) . This is key to both, adequate patient management, based on informed decision processes, clinical trial design and outcome interpretation.
In heterogeneous tumors such as PDAC, biopsies carry a significant risk of tissue undersampling. In contrast, imaging inhabits a unique niche in precision medicine in that it can provide volumetric information non-invasively. Radiomics, the process of derivation of quantitative analytics from medical imaging data (4) represents a significant advance over traditional image-analysis workflows as it leverages data science and machine learning techniques to exploit non-intuitive image content and integrate it with clinical information to create a generalizable model capable of predicting e.g. biological features or the course of disease (5) .
Since PDAC is a relatively rare tumor entity, typically only treated in specialized interdisciplinary centers, there is still a paucity of radiomic studies aiming to assess pertinent metrics such as patient survival or histopathological subtypes. Our study aims to contribute to this field by applying a standardized, reproducible radiomic workflow pipelined to an efficient and explainable machine learning model capable of predicting overall survival and showing highly significant correlation with relevant histopathological subtypes, retrospectively trained and prospectively validated on a cohort of PDAC patients.
Methods

Study design
Data collection, processing and analysis were approved by the institutional ethics committee (Ethics Commission of the Faculty of Medicine, protocol numbers 180/17 and 5573/12). The study was designed as a retrospective cohort study with a prospective validation cohort. The requirement for written consent was waived for the retrospective cohort and written consent was obtained for the prospective cohort. All procedures were carried out in accordance to pertinent laws and regulations.
We considered patients with final histopathological diagnosis of PDAC of the head and body for inclusion in the study. Patients who did not have a final diagnosis of PDAC, had undergone treatment such as chemotherapy or resection prior to enrolment, refused treatment or study inclusion, died within the first 2 months of follow-up (to limit bias from postoperative complications), did not undergo the full imaging protocol or did not have technically sufficient imaging available, were excluded. For inclusion in the training cohort, we retrospectively 
Clinical variables
The following clinical data was collected for patients in the training and external validation cohorts: age at diagnosis, sex, p/cTNM, R, G, tumor volume (from the final histopathological report or calculated from the segmentation volume), ECOG-state and chemotherapy regimen.
Where applicable and available, pre-operative CA19-9 levels and lymph-node ratios (LNR) were noted. Overall survival was defined as the time from diagnosis to disease-related death. 
Data segmentation
Pseudonymized datasets were exported from the hospital picture archiving system (PACS) onto a radiological workstation and segmented under reporting room conditions by consensus reading of 2 experienced observers (G.K. and S.Z.) and quality-controlled by an abdominal radiologist with >10 years of experience in pancreatic MRI (R.B.). Segmentation was performed manually in the b=600 images and transferred to the ADC maps. All other sequences were available to observers for anatomical correlation.
Inferential statistical modeling
For assessing potential clinical confounding parameters introducing bias to the survival prediction, survival time was modeled in both cohorts using a multivariate Cox proportional hazards model. The distributions of clinical variables were compared between groups using
Fisher's exact test. For subsequent machine learning modeling, the two cohorts were dichotomized by median overall survival to yield two sub-cohorts of equal size. ROCthresholds were evaluated with the Kolmogorov-Smirnov-statistic. Biostatistical modeling was performed in SPSS Version 25. For all inferential statistical procedures, a P-value of <0.05 was considered statistically significant.
Image postprocessing, radiomic feature extraction and machine learning modeling All steps of image postprocessing, feature extraction, feature preprocessing, feature engineering and machine learning modeling are detailed in the supplemental material. In brief, radiomic features were derived using PyRadiomics (v. 2.1 (6)) yielding a total of 1688 features, of which 504 were retained after preprocessing. A Random Forest (7) classifier was fit in a supervised fashion with survival above versus below median serving as label to the training cohort radiomic features and tested for predictive sensitivity, specificity and ROC-AUC in the external validation cohort. Feature importance was assessed to derive significant radiomic features for the model. All analyses were carried out using the Python programming language.
Histopathological workup of tumor samples
Histopathological staining and immunohistochemical workup were performed as described in Furthermore, the algorithm's predictions enabled statistically significant stratification of abovevs. below-median overall survival in the external validation cohort (log-rank-test P <0.001, predicted median survival for the below-median 17.0 months vs. 31.3 months for the abovemedian group) with the resulting predicted survival curves showing near-perfect overlap with the actual survival times of the patients (Fig. 2) .
The histopathologic subtype of the tumor samples could be determined for 21 of the 30 patients in the external validation cohort. The quasi-mesenchymal histopathological tumor subtype was greatly overrepresented in the patient collective predicted by the algorithm to experience below-median survival with 8 out of 9 patients having quasi-mesenchymal subtype tumors.
The opposite also held true, with 11 out of 12 patients predicted by the algorithm to experience above-median survival having non-quasi-mesenchymal subtype tumors (Fisher's exact test P<0.001, Table 1 ).
Feature importance evaluation yielded 8 highly important features (Fig. 3) . 
Discussion
In this work we present a prospectively validated machine learning algorithm, which enables the prediction of overall survival and shows strong association with histopathologically defined molecular subtypes recently identified in PDAC. Several of the most important imaging features belong to a class of heterogeneity related features, offering explainable insights into the algorithm.
The potential of radiomics in non-invasive prediction of clinically relevant parameters, such as response to a specific therapy or expected overall survival has been shown in recent literature:
For example, CT-derived radiomic signatures were shown to enable prediction of local disease control and overall survival in PDAC (11, 12) or tumor grading in pancreatic neuroendocrine tumors (13) . The large-scale implementation of such tools thus has the potential to become a game changer in medical image interpretation and individualized patient care.
Post mortem analyses of terminal stage PDAC specimens have shown higher tumor cellularity compared to resectable PDAC specimens, which likely represent earlier tumor development stages (14) . In line with this observation we previously demonstrated that higher regional tumor cellularity identified in PDAC resection specimens was associated with a significantly worse overall survival and that the pre-operative DW-MRI-derived ADC parameter could serve as a non-invasive marker thereof (15, 16) . Upholding these findings, the current analysis identified predictive of overall survival in PDAC (12) . Entropy has furthermore been found to represent a highly reproducible and consistent imaging feature in several tumor entities and across modalities (17) . The discovery of such reproducible parameters is a key part of the radiomic process and it is encouraging to see the same radiomic markers emerge not only across pancreatic cancer studies but also in other tumor entities and across different MRI systems and field strengths, supporting assumptions of overarching ontologies such as tumor heterogeneity and paralleling the notions of pathway-as opposed to tissue-specific therapy approaches (18) . We selected the Random Forest model over the frequently-used linear models such as logistic regression for its capability of modeling both linear and non-linear relationships between features and outcomes, robustness to overfitting by design, and inbuilt insights into feature importance aiding model parsimony and explainability. Random Forests have also been shown to yield excellent results in previously published radiomic studies (22) .
As part of any radiomic study, feature preprocessing and stability checking is required to obtain reproducible results, resulting in the majority of derived features being discarded before modeling begins (23) . These discarded features are therefore rendered useless for the modeling process. To obtain more usable features, standardized acquisition and feature extraction is necessary. Recent initiatives aim to homogenize acquisition protocols between sites to enable further sequences to be included in analyses (24). We adhered to (and strongly support) the standards set by IBSI/PyRadiomics (6,10), which provide a robust postprocessing platform entirely based on open-source tools, thus laying the foundation for open and reproducible radiomic science.
Our work is a proof of concept contribution to the fast-developing field of machine learning in medical imaging. Notable limitations include training cohort size, due to which the model could not reach its full potential performance (see the training curve in the supplemental material).
The age of the imaging material in the retrospective training cohort also impacted results with several patients being excluded due to technical image quality. The quality of MRI acquisitions has since considerably improved and our results could benefit from the application of state-ofthe art abdominal imaging including high resolution protocols, such as reduced field-of-view DWI (25) (26) (27) . We eliminated all features that were classified unstable between the two MRI systems and recent research has provided evidence that the quantitative nature of ADC maps results in large numbers of stable features in different tumor entities and across different field strengths and MRI systems (28) . Despite that, the impact of switching MRI systems between the two cohorts cannot yet be conclusively resolved. Lastly, although rigorously qualitycontrolled, our approach still relies on manual tumor segmentation, since recent fullyautomated segmentation algorithms fail to match human observers in pancreatic tumors (29) .
We believe that future work will result in optimized algorithms that enable a higher level of automation -and thus standardization-of this task.
In conclusion, we show the promise of machine learning-based radiomic analyses in PDAC.
We encourage the validation of the identified radiomic parameters in larger, prospectively accrued cohorts to lay the foundation for therapeutic interventions based on quantitative imaging biomarkers. 
